Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancer

BMC Medical Genetics volume 20, Article number: 162 (2019) Cite this article

Abstract

Background

Several studies have focused on the relationship between MMP-8 variants and cancer risk, but they have been unsuccessful in drawing reliable conclusions.

Methods

We employed odds ratio (OR) together with 95% confidence interval (CI) to assess the correlation between MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms and cancer risk. We further employed in silico tools to evaluate the effect of MMP-8 expression on cancer susceptibility and overall survival time.

Results

A total of 8140 patients with malignant carcinoma and 10,529 healthy individuals (control) were enrolled. Overall, the analysis showed that the relationship between three MMP-8 variants and cancer susceptibility was not significant (allelic contrast, C-799 T: OR = 0.98, 95% CI = 0.92–1.04, Pheterogeneity = 0.068; Lys460Thr: OR = 0.94, 95% CI = 0.67–1.32, Pheterogeneity = 0.905; Lys87Glu: OR = 1.05, 95% CI = 0.93–1.18, Pheterogeneity = 0.968). Similar results were observed in subgroup analysis by ethnicity, cancer type, and source of control. In silico analysis indicated that MMP-8 expression was elevated in bladder cancer tissue compared to that in the control. However, both the higher and lower MMP-8 expression groups did not show an impact on the overall survival time of the patients.

Conclusions

MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not participant with the susceptibility of cancer.

Peer Review reports

Background

It is well-known that the development of carcinoma is complex and has not been completely clarified. Hereditary material and genetic polymorphisms may probably have an impact on cancer susceptibility and play a crucial role in the tumorigenesis of numerous carcinomas [1,2,3,4]. Previous studies have shown evidence that the genetic aspects measured by single nucleotide polymorphisms (SNPs) might be associated with cancer susceptibility [5,6,7,8]. Matrix metalloproteinases (MMPs) belong to a family of endopeptidases that can degrade various extracellular matrix proteins and treat numerous extracellular matrix (ECM) components [9, 10]. Accumulated evidence has indicated that MMPs may have a critical role in cell inflammation, migration and carcinogenesis [11,12,13]. Increased levels of MMPs have been observed in the specimens of a number of cancer subjects, such as urinary bladder cancer, lung cancer, breast cancer, and malignant melanoma [14]. Among the MMPs, MMP8 is a collagen-cleaving enzyme present in connective tissue. The MMP8 is not only produced by neutrophils but also synthesized by a series of malignant tumor cells [15, 16]. High level of MMP8 was reported in the fluid of ovarian cancer compared to control tissue [17].

Previous studies have showed evidence that genetic mutations and variants can predispose for malignant tumors [18, 19]. Human MMP-8 gene comprises twelve exons and is located on chromosome 11q22.3 [20]. Polymorphisms of MMP8 can lead to gene dysfunction, microenvironment disorder and potential carcinogenesis. It has been reported that several single nucleotide polymorphisms (SNPs) of MMP8 can influence the gene expression by altering its promoter activity. In addition, the T allele of MMP8 C-799 T variant was reported to be related to breast carcinoma susceptibility and lymph node metastasis among Asian and Caucasian population [21]. Furthermore, electrophoresis mobility shift assays have demonstrated that the difference in nucleoprotein binding to oligodeoxynucleotides was correlated with MMP8 C-799 T variation [22]. However, Wieczorek et al. indicated that genetic variation in MMP8 C-799 T was not associated with urinary bladder cancer susceptibility in Caucasian descendants [23].

A number of studies have evaluated the association of MMP8 genetic variants including C-799 T (rs11225395 C/T), Lys460Thr (rs35866072 A/C), and Lys87Glu (rs1940475 G/A) SNPs, with cancer risk. Research on these MMP8 variations have been carried out in numerous countries, such as USA, Mexico, Poland, India, Korea, and China [23,24,25,26,27,28,29,30,31,32,33,34,35]. Nevertheless, there were controversial results on the relationship between MMP8 variations and various cancers among different case control studies. Therefore, we conducted a comprehensive analysis based on accumulated data of all eligible studies to investigate the impact of MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms on overall cancer susceptibility.

Methods

Database searching and screening process

Comprehensive literature search on PubMed, Web of Science, EMBASE (Excerpta Medica Database), and SinoMed (China Wanfang Databases) was carried out to identify all eligible case-control studies, prior to June 2019. Valid keyword search strings are as follows: (MMP-8 OR matrix metalloproteinases 8) AND (polymorphism OR variant OR mutation OR SNP) AND (carcinoma OR tumor OR malignancy OR cancer). Furthermore, we independently retrieved the references in the identified articles to screen other available studies, with no language restriction. For studies with overlapping data, we selected the most recently published ones.

Inclusion and exclusion criteria

Eligible studies should meet the following inclusion criteria: (a) evaluate the relationship between MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms and cancer risk; (b) case-control study; and (c) contain available data on the frequency of genotypes. We independently excluded unpublished case reports, letters, reviews, meta-analyses, or missing genotype data for C-799 T, Lys460Thr, and Lys87Glu variants. We also excluded the studies that focused only on the case population.

Data extraction and quality assessment

Two authors (LFZ and YYM) independently completed the data extraction based on the selection criteria. Any potential disagreement was discussed comprehensively to obtain a final consensus. The main features of included studies are summarized, which includes: first author’s name, year of publication, origin and race, type of cancer, age range, total number of participants, genotyping assay of MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants in cases and controls, P-value of Hardy-Weinberg equilibrium (HWE) in controls. The quality score of the eligible studies was evaluated by Newcastle-Ottawa Scale (NOS). The research was regarded as high-quality if it acquired six or more stars.

Statistical analysis

We calculated the OR with 95% CI to investigate the strength of the relationship between MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms and cancer susceptibility. A total of five genetic models were adopted: allelic contrast (M-allele vs. W-allele, for C-799 T, T vs. C; for Lys460Thr, C vs. A; for Lys87Glu, A vs. G), homozygote model (MM vs. WW, for C-799 T, TT vs. CC; for Lys460Thr, CC vs. AA; for Lys87Glu, AA vs. GG), heterozygote model (MW vs. WW, for C-799 T, TC vs. CC; for Lys460Thr, CA vs. AA; for Lys87Glu, AG vs. GG), dominant comparison (MM + MW vs. WW, for C-799 T, TT + TC vs. CC; for Lys460Thr, CC+ CA vs. AA; for Lys87Glu, AA + AG vs. GG), recessive comparison (MM vs. MW + WW, for C-799 T, TT vs. TC + CC; for Lys460Thr, CC vs. CA + AA; for Lys87Glu, AA vs. AG + GG). Q-test was utilized to estimate the heterogeneity among enrolled researches. If the heterogeneity was absent (P > 0.05), the fixed-effects model was employed [36]; alternatively, the random-effects model was performed [37]. Stratified analyses were carried out according to race (Asian, Caucasian, and Latin), type of cancer (bladder cancer and other cancers), and source of control. Hardy-Weinberg equilibrium (HWE) in the control group was calculated using a Chi-squared test. Begg’s funnel plot and the Egger’s test were both performed to measure the possible publication bias. P values of Begg’s and Egger’s test more than 0.05 indicated the absence of publication bias. The STATA software (Version 11.0, Stata Corporation, College Station, TX, USA) was adopted for all the above analyses.

In silico analysis of MMP-8

To further investigate whether the expression of MMP-8 has an impact on tumorigenesis, we employed the online TCGA database to evaluate the MMP-8 expression in bladder cancer tissue and control counterparts. The effect of the expression of MMP-8 on bladder cancer patients’ overall survival time was also assessed. Furthermore, we adopted bioinformatics tools, like Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), to predict the role of MMP-8 SNPs at the protein level.

Results

Characteristics of included studies

Main characteristics of the eligible articles as well as the genotyping assay results of MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants have been summarized in Table 1. A total of 13 publications containing 19 case-control studies for the MMP-8 polymorphisms in compliance with the inclusion criteria were finally identified in the present analysis. All eligible studies had NOS score more than 6. There were 4372 cancer patients and 5066 control participants for the analysis of MMP-8 C-799 T variant. Five articles were acquired for assessing the association of MMP-8 Lys460Thr variant on cancer susceptibility, including 3019 cases and 3544 control subjects. There were 749 cases and 1919 controls on the Lys87Glu polymorphism. The MAFs (minor allele frequencies) of MMP-8 C-799 T variants were shown in Fig. 1: African, 0.185; East Asian, 0.423; European, 0.411; South Asian, 0.350; and American, 0.440. For MMP-8 Lys460Thr polymorphism: African, 0.222; East Asian, 0.009; European, 0.044; South Asian, 0.060; and American, 0.060. The MAFs for Lys87Glu variant were: African, 0.290; East Asian, 0.432; European, 0.453; South Asian, 0.400; and American, 0.480. In stratified analysis by race, 13 case-control studies were conducted on Asian descendants; five were based on the Caucasian population and one was based on Latin descendants. In stratified analysis by cancer type, four studies concerned bladder cancer. The rest were focused on other cancers, such as lung cancer, hepatocellular carcinoma, malignant melanoma, oral cancer, ovary cancer, and gastric cancer. In stratified analysis by the source of control, 12 studies were population-based controls, and the rest seven were hospital-based studies.

Table 1 Basic information of included studies for MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants and overall cancer risk
Full size table
Fig. 1
figure 1

Minor allele and major allele frequencies for MMP-8 C-799 T (a), Lys460Thr (b), and Lys87Glu (c) variants in controls stratified by ethnicity. Vertical line, allele frequency; Horizontal line, allele type

Full size image

Quantitative synthesis

Summarized results and details of the present analyses for the three MMP-8 polymorphisms and cancer risk are provided in Table 2. Overall analysis indicated that the relationship between the three MMP-8 variants and cancer susceptibility was not significant. The MMP-8 C-799 T variant is not associated with the susceptibility of cancer under all genetic models (allele contrast: OR = 0.98, 95% CI = 0.92–1.04, Pheterogeneity = 0.068, P = 0.429; TT vs. CC: OR = 0.94, 95% CI = 0.82–1.07, Pheterogeneity = 0.097, P = 0.362; heterozygote comparison: OR = 1.00, 95% CI = 0.92–1.09, Pheterogeneity = 0.193, P = 0.992; TT + TC vs. CC: OR = 0.98, 95% CI = 0.90–1.07, Pheterogeneity = 0.086, P = 0.666; recessive model: OR = 0.94, 95% CI = 0.83–1.07, Pheterogeneity = 0.249, P = 0.348). In subgroup analysis by cancer type, we also indicated no relationship between MMP-8 C-799 T variant and bladder cancer (T vs. C: OR = 0.97, 95% CI = 0.83–1.12, P = 0.671, Fig. 2; TT vs. CC: OR = 0.85, 95% CI = 0.61–1.17, P = 0.316; TC vs. CC: OR = 1.08, 95% CI = 0.87–1.33, P = 0.492; TT + TC vs. CC: OR = 1.02, 95% CI = 0.84–1.25, P = 0.813; TT vs. TC + CC: OR = 0.83, 95% CI = 0.61–1.12, P = 0.219) or other cancers (T vs. C: OR = 0.99, 95% CI = 0.89–1.11, P = 0.898; TT vs. CC: OR = 0.96, 95% CI = 0.83–1.11, P = 0.578; TC vs. CC: OR = 0.99, 95% CI = 0.89–1.09, P = 0.763; TT + TC vs. CC: OR = 1.00, 95% CI = 0.86–1.16, P = 0.965; TT vs. TC + CC: OR = 0.97, 95% CI = 0.84–1.11, P = 0.631). In stratified analysis by race and source of control, no significant association between this polymorphism and cancer susceptibility was demonstrated (Fig. 3). For the MMP-8 Lys460Thr variant, we also indicated no major association of this variant on cancer risk (C vs. A: OR = 0.94, 95% CI = 0.67–1.32, Pheterogeneity = 0.905, P = 0.729; CC vs. AA: OR = 0.83, 95% CI = 0.36–1.93, Pheterogeneity = 0.859, P = 0.669; CA vs. AA: OR = 1.00, 95% CI = 0.66–1.50, Pheterogeneity = 0.904, P = 0.994; TT + TC vs. CC: OR = 0.96, 95% CI = 0.67–1.40, Pheterogeneity = 0.886, P = 0.848; recessive model: OR = 0.83, 95% CI = 0.36–1.93, Pheterogeneity = 0.866, P = 0.669, Table 2). In addition, similar results were revealed for the association between the MMP-8 Lys87Glu variant and cancer risk in allelic contrast (OR = 1.05, 95% CI = 0.93–1.18, P value for heterogeneity = 0.968, P = 0.430); homozygote model (OR = 1.11, 95% CI = 0.88–1.42, Pheterogeneity = 0.953, P = 0.377); heterozygote comparison (OR = 0.96, 95% CI = 0.78–1.18, P value for heterogeneity = 0.647, P = 0.722); dominant model (OR = 1.01, 95% CI = 0.83–1.22, Pheterogeneity = 0.863, P = 0.928), and recessive comparison (OR = 1.13, 95% CI = 0.93–1.38, Pheterogeneity = 0.604, P = 0.222).

Table 2 Stratified analyses of MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants on overall cancer risk
Full size table
Fig. 2
figure 2

Forest plot of allelic contrast of MMP-8 C-799 T polymorphism in the stratified analyses by cancer type (fixed-effects)

Full size image
Fig. 3
figure 3

Forest plot of cancer risk associated with MMP-8 C-799 T variant (allelic comparison of T-allele vs. C-allele, fixed-effects) in the stratified analyses by ethnicity

Full size image

In silico analysis of MMP-8

Results from the TCGA database, containing 408 primary tumor and 19 normal samples, revealed that MMP-8 expression was elevated in bladder cancer tissue as compared to their control counterpart (P < 0.01, Fig. 4a). Furthermore, we investigated whether the MMP-8 expression had an effect on the overall survival time of bladder carcinoma participants. However, neither higher MMP-8 expression group nor lower expression group would have an impact on the patients’ overall survival time (P < 0.05, Fig. 4b, c). In addition, we adopted the Polyphen-2 bioinformatics tool to analyze the associations between MMP-8 Lys460Thr (K460 T, rs35866072), and Lys87Glu (K87E, rs1940475) variants and protein damage. Mutations of these SNPs are predicted to be “BENIGN” with a score less than 0.05, which indicated that neither Lys460Thr nor Lys87Glu SNP may probably damage the protein of MMP-8 (Fig. 5).

Fig. 4
figure 4

In silico analysis of MMP-8 expression in bladder cancer (a). Association of the expression of MMP-8 and the overall survival (OS) time among bladder cancer participants (b, c)

Full size image
Fig. 5
figure 5

Polyphen2 bioinformatics tools for assessing the association between MMP-8 Lys460Thr (K460 T, rs35866072, a), Lys87Glu (K87E, rs1940475, b) variants and protein damaging (The place of black line represents the score)

Full size image

Publication bias

Both Egger’s and Begg’s funnel plot were employed for appraisal of the publication bias when evaluating MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants. No evidence of publication bias was acquired for MMP-8 C-799 T polymorphism (T-allele vs. C-allele, t = 0.37, P = 0.722; TT versus CC, t = 0.26, P = 0.801; TC vs. CC, t = 0.59, P = 0.567; TT + TC versus CC, t = 0.62, P = 0.552; TT versus TC + CC, t = 0.07, P = 0.945). For MMP-8 Lys460Thr variant: M-allele vs. W-allele, t = − 0.35, P = 0.752; MW vs. WW, t = − 0.71, P = 0.527; MM + MW vs. WW, t = − 0.68, P = 0.545. For Lys87Glu variant: A vs. G, t = 0.38, P = 0.771; AA vs. GG, t < − 0.01, P = 0.998; AG vs. GG, t = − 0.04, P = 0.975; AA + AG vs. GG, t = − 0.13, P = 0.916; AA vs. AG + GG, t = 1.71, P = 0.338. Outlines of the funnel plots were relatively symmetrical for overall cancer risk, implying no significant publication bias (Fig. 6).

Fig. 6
figure 6

Begg’s funnel plot of standard error for investigating publication bias of MMP-8 C-799 T (a), Lys460Thr (b), and Lys87Glu (c) variants under T-allele vs. C-allele genetic model

Full size image

Discussion

The MMP-8 serves as one of the most efficient collagenases and plays an essential role in carcinoma invasion and metastasis. Previous research demonstrated that advanced metastatic stage and further poor prognosis of carcinoma might be related to elevated expression of MMPs [38, 39]. Additionally, it was hypothesized that the regulatory effect of MMPs could be associated with variations in the MMP genes. One group reported that the MMP8 C-799 T variant might be related to breast carcinoma susceptibility and lymph node metastasis in Asians and Caucasians [21]. However, another group investigated MMP8 variations among a representative Taiwanese breast carcinoma population and indicated no significant relationship between MMP-8 C-799 T, and Lys460Thr polymorphisms and cancer risk [34]. Therefore, it is reasonable to summarize all eligible data and draw more accurate conclusions to evaluate the contribution of MMP-8 polymorphisms to cancer risk. Furthermore, we employed the TCGA database and Polyphen2 bioinformatics tools to assess the role of MMP-8 expression on cancer risk and survival time.

In the present study, a total of 8140 patients with malignant carcinoma and 10,529 control participants were investigated. For MMP-8 C-799 T polymorphism, we observed no significant relationship with cancer risk (z-value = 0.79, Pheterogeneity = 0.068, P = 0.429, allelic contrast). Our finding was in agreement with the studies conducted by Hsiao et al., Huang et al., and Wieczorek et al [23, 31, 34]. In subgroup analysis by cancer type, this variation did not significantly confer susceptibility to urinary bladder cancer (z-value = 0.43, Pheterogeneity = 0.286, P = 0.671) and other cancers (z-value = 0.13, Pheterogeneity = 0.039, P = 0.898). In stratified analysis by race, a similar result was indicated in Asian (z-value = 1.54, Pheterogeneity = 0.248, P = 0.125) and Caucasian descendants (z-value = 1.87, Pheterogeneity = 0.082, P = 0.062). For MMP-8 Lys460Thr variant, no positive correlation was found in the overall analysis (z-value = 0.35, Pheterogeneity = 0.905, P = 0.729). Similar results were indicated for Lys87Glu variant (z-value = 0.79, Pheterogeneity = 0.968, P = 0.430). Results from in silico analysis showed that MMP-8 expression was elevated in bladder cancer tissue as compared to the control counterpart. However, both the higher and lower MMP-8 expression groups did not have an impact on the patients’ overall survival time. Moreover, Polyphen-2 bioinformatics tool was also adopted to confirm the results of our present analysis. As the report for MMP-8 C-799 T (rs11225395) variation was not available, the association between Lys460Thr (K460 T, rs35866072), and Lys87Glu (K87E, rs1940475) variants and protein damaging was further investigated. Mutations of Lys460Thr and Lys87Glu were predicted to be “BENIGN” with a score less than 0.05, which indicated that these SNPs do not damage MMP-8 protein, and are in agreement with the conclusions of the current analyses.

In addition, several limitations of the present study should be clarified. First of all, the number of enrolled studies for subgroup analysis remains insufficient, which exhibits fairly limited statistical power. Only five studies for MMP-8 Lys460Thr SNPs and three for Lys87Glu polymorphism were acquired based on the selection criteria. As regard to C-799 T variant, only two case-control studies were focused on Caucasian population and one was based on Latin descendants. In addition, tumor stage and grade may potentially influence the results of the present analysis. We tried to further evaluate this effect in more details; however, raw data of eligible studies remains insufficient. More efficient investigations are still required to further strengthen the statistical power. Last but not least, P value for HWE was less than 0.05 in five of the included articles [30, 31, 33,34,35], which might be exposed to unknown bias factors.

Despite these limitations, some key advantages should be acknowledged. First, all eligible case-control studies according to the selection criteria were obtained and the statistical efficiency was enhanced remarkably. Second, no obvious publication bias was indicated by Egger’s and Begg’s funnel plot, which showed that the findings of the current analysis can be considered reliable. Additionally, NOS scores of the enrolled studies were more than 6, which indicated a high methodological quality of each article.

Conclusions

Taken together, based on the currently published data, our study showed evidence that MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not participant with the susceptibility of cancer. Further well-designed investigations are still warranted to confirm this conclusion in more detail.

Availability of data and materials

All the data generated in the present research is contained in this manuscript.

Abbreviations

BCa:

Bladder cancer

HB:

Hospital-based

HCa:

Hepatocellular carcinoma

HWE:

Hardy-Weinberg equilibrium of controls

M-allele:

Mutant allele

MM:

Malignant melanoma

NA:

Not available

NOS:

Newcastle–Ottawa Scale

PB:

Population-based

PCR-RFLP:

Polymerase chain reaction and restrictive fragment length polymorphism

RT:

Real time

W-allele:

Wild-type allele

References

  1. Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: recent progress and future directions. Adv Cancer Res. 2010;109:51–72.

    Article  CAS  Google Scholar 

  2. Marshall AL, Christiani DC. Genetic susceptibility to lung cancer--light at the end of the tunnel? Carcinogenesis. 2013;34(3):487–502.

    Article  CAS  Google Scholar 

  3. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007;4(2):59–71.

    Article  CAS  Google Scholar 

  4. Shao HB, Ren K, Gao SL, Zou JG, Mi YY, Zhang LF, et al. Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancer. Aging (Albany NY). 2018;10(7):1776–88.

    Article  CAS  Google Scholar 

  5. Ge J, Liu H, Qian D, Wang X, Moorman PG, Luo S, et al. Genetic variants of genes in the NER pathway associated with risk of breast cancer: a large-scale analysis of 14 published GWAS datasets in the DRIVE study. Int J Cancer. 2019. https://doi.org/10.1002/ijc.32371 [Epub ahead of print].

  6. Zhang LF, Ren KW, Zuo L, Zou JG, Song NH, Mi YY, et al. VEGF gene rs3025039C/T and rs833052C/A variants are associated with bladder cancer risk in Asian descendants. J Cell Biochem. 2019;120(6):10402–12.

    Article  CAS  Google Scholar 

  7. Alekseeva IV, Davletgildeeva AT, Arkova OV, Kuznetsov NA, Fedorova OS. The impact of single-nucleotide polymorphisms of human apurinic/apyrimidinic endonuclease 1 on specific DNA binding and catalysis. Biochimie. 2019;163:73–83.

    Article  CAS  Google Scholar 

  8. Ding WH, Ren KW, Yue C, Zou JG, Zuo L, Zhang LF, et al. Association between three genetic variants in kallikrein 3 and prostate cancer risk. Biosci Rep. 2018;38(6):1–11.

    Article  Google Scholar 

  9. Lekstan A, Lampe P, Lewin-Kowalik J, Olakowski M, Jablonska B, Labuzek K, et al. Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma. J Physiol Pharmacol. 2012;63(6):589–99.

    CAS  PubMed  Google Scholar 

  10. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.

    Article  CAS  Google Scholar 

  11. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696–701.

    Article  CAS  Google Scholar 

  12. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20(3):161–8.

    Article  CAS  Google Scholar 

  13. Zhang LF, Mi YY, Cao Q, Wang W, Qin C, Wei JF, et al. Update analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk. Mol Biol Rep. 2012;39(4):3435–41.

    Article  CAS  Google Scholar 

  14. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58(7):1395–9.

    CAS  PubMed  Google Scholar 

  15. Stadlmann S, Pollheimer J, Moser PL, Raggi A, Amberger A, Margreiter R, et al. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur J Cancer. 2003;39(17):2499–505.

    Article  CAS  Google Scholar 

  16. Sirniö P, Tuomisto A, Tervahartiala T, Sorsa T, Klintrup K, Karhu T, et al. High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer. Br J Cancer. 2018;119(2):213–9.

    Article  Google Scholar 

  17. Stenman M, Paju A, Hanemaaijer R, Tervahartiala T, Leminen A, Stenman UH, et al. Collagenases (MMP-1, −8 and −13) and trypsinogen-2 in fluid from benign and malignant ovarian cysts. Tumour Biol. 2003;24(1):9–12.

    Article  CAS  Google Scholar 

  18. Smith KR, Hanson HA, Mineau GP, Buys SS. Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci. 2012;279(1732):1389–95.

    Article  CAS  Google Scholar 

  19. Voskarides K. Combination of 247 genome-wide association studies reveals high cancer risk as a result of evolutionary adaptation. Mol Biol Evol. 2018;35(2):473–85.

    Article  CAS  Google Scholar 

  20. Pendás AM, Santamaría I, Alvarez MV, Pritchard M, López-Otín C. Fine physical mapping of the human matrix metalloproteinase genes clustered on chromosome 11q22.3. Genomics. 1996;37(2):266–8.

    Article  Google Scholar 

  21. Decock J, Long JR, Laxton RC, Shu XO, Hodgkinson C, Hendrickx W, et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007;67(21):10214–21.

    Article  CAS  Google Scholar 

  22. Wang H, Parry S, Macones G, Sammel MD, Ferrand PE, Kuivaniemi H, et al. Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum Mol Genet. 2004;13(21):2659–69.

    Article  CAS  Google Scholar 

  23. Wieczorek E, Reszka E, Wasowicz W, Grzegorczyk A, Konecki T, Sosnowski M, et al. MMP7 and MMP8 genetic polymorphisms in bladder cancer patients. Cent Eur J Urol. 2014;66(4):405–10.

    Google Scholar 

  24. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006;66(24):11644–8.

    Article  CAS  Google Scholar 

  25. Nan H, Niu T, Hunter DJ, Han J. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. Cancer Epidemiol Biomark Prev. 2008;17(12):3551–7.

    Article  CAS  Google Scholar 

  26. Qiu W, Zhou G, Zhai Y, Zhang X, Xie W, Zhang H, et al. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol Biomark Prev. 2008;17(9):2514–8.

    Article  CAS  Google Scholar 

  27. Dębniak T, Jakubowska A, Serrano-Fernández P, Kurzawski G, Cybulski C, Chauhan SR, et al. Association of MMP8 gene variation with an increased risk of malignant melanoma. Melanoma Res. 2011;21(5):464–8.

    Article  Google Scholar 

  28. Kim JH, Pyun JA, Lee KJ, Cho SW, Kwack KB. Study on association between single nucleotide polymorphisms of MMP7, MMP8, MMP9 genes and development of gastric cancer and lymph node metastasis. Korean J Gastroenterol. 2011;58(5):245–51.

    Article  CAS  Google Scholar 

  29. Srivastava P, Kapoor R, Mittal RD. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol. 2013;31(2):247–54.

    Article  CAS  Google Scholar 

  30. Arechavaleta-Velasco F, Cuevas-Antonio R, Dominguez-Lopez P, Estrada-Moscoso I, Imani-Razavi FS, Zeferino-Toquero M, et al. Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer. Med Oncol. 2014;31(8):132.

    Article  Google Scholar 

  31. Hung YW, Tsai CW, Wu CN, Shih LC, Chen YY, Liu YF, et al. The contribution of matrix metalloproteinase-8 promoter polymorphism to oral cancer susceptibility. In Vivo. 2017;31(4):585–90.

    Article  CAS  Google Scholar 

  32. Pei JS, Chang WS, Hsu PC, Hung YW, Cheng SP, Tsai CW, et al. The contribution of MMP-8 promoter genotypes to childhood leukemia. In Vivo. 2017;31(6):1059–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Shen TC, Hsia TC, Chao CY, Chen WC, Chen CY, Chen WC, et al. The contribution of MMP-8 promoter polymorphisms in lung cancer. Anticancer Res. 2017;37(7):3563–7.

    CAS  PubMed  Google Scholar 

  34. Hsiao CL, Liu LC, Shih TC, Chuang CL, Chen GL, Wang HC, et al. The association of matrix metalloproteinase-8 promoter genotypes in breast cancer. Anticancer Res. 2018;38(4):2181–5.

    CAS  PubMed  Google Scholar 

  35. Tsai TH, Wang YM, Chang WS, Tsai CW, Wu HC, Hsu HM, et al. Association of Matrix Metalloproteinase-8 genotypes with the risk of bladder cancer. Anticancer Res. 2018;38(9):5159–64.

    Article  CAS  Google Scholar 

  36. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    CAS  Google Scholar 

  37. Barili F, Parolari A, Kappetein PA, Freemantle N. Statistical primer: heterogeneity, random- or fixed-effects model analyses? Interact Cardiovasc Thorac Surg. 2018;27(3):317–21.

    Article  Google Scholar 

  38. Szarvas T, vom Dorp F, Ergün S, Rübben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol. 2011;8(5):241–54.

    Article  CAS  Google Scholar 

  39. O'Mara TA, Clements JA, Spurdle AB. The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors. Cancer Epidemiol Biomark Prev. 2009;18(9):2352–65.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by National Natural Science Foundation (Number: 81802576, 81902565, 81871151), Traditional Chinese Medicine Administration Fund of Jiangsu Province (No. YB201827), Changzhou High-Level Medical Talents Training (Project No. RC201620), Commission of Health and Family Planning of Wuxi (Project No.: J201803, Q201811, Z201712, J201810, Q201746, jzyx03), Jiangsu Province Medical Key Talent (ZDRCA2016009), Medical Young Talent of Wuxi City (QNRC043), Young Scientists Foundation of Changzhou No.2 People’s Hospital (2019 K008), Jiangsu Post-Doc Scientific Research Grant (QT201710, QT201709), Sci & Tech program of Changzhou (CJ20190100), Science and Technology Development of Wuxi (WX18IIAN024, CSE31N1605). The above funding bodies were financial support and were not involved in the study design, data analysis, writing of the manuscript or other aspect of this research.

Author information

Author notes

  1. Li-Feng Zhang, Li-Jie Zhu, Wei Zhang and Wei Yuan contributed equally to this work.

Authors and Affiliations

  1. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    Li-Feng Zhang, Ning-Hong Song, Zeng-Jun Wang & Wei Zhang

  2. Department of Urology, The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, Changzhou, 213003, Jiangsu Province, China

    Li-Feng Zhang & Li Zuo

  3. Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, 214000, China

    Li-Jie Zhu & Yuan-Yuan Mi

  4. Department of Oncology, Taizhou People’s Hospital, Taizhou, 225300, Jiangsu, China

    Wei Zhang

  5. Department of Cardiology, Taizhou People’s Hospital, Taizhou, 225300, Jiangsu, China

    Wei Yuan

Authors
  1. Li-Feng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li-Jie Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ning-Hong Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Zuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuan-Yuan Mi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zeng-Jun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NHS and LZ designed and conceived this study. WY, LJZ and WZ1 contributed to literature searching. LFZ and YYM were involved in data extraction. YYM, ZJW, and WZ2 analyzed the data. LFZ, WY and WZ1 wrote the manuscript. NHS and LZ revised the paper. All authors have approved the final edition of the manuscript. (“WZ1” corresponding to Wei Zhang from Jiangsu Taizhou People’s Hospital. “WZ2” corresponding to Wei Zhang from The First Affiliated Hospital of Nanjing Medical University.)

Corresponding authors

Correspondence to Ning-Hong Song, Li Zuo or Yuan-Yuan Mi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, LF., Zhu, LJ., Zhang, W. et al. MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancer. BMC Med Genet 20, 162 (2019). https://doi.org/10.1186/s12881-019-0890-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12881-019-0890-z

Keywords

BMC Medical Genetics

ISSN: 1471-2350

Contact us